Psoriasis Clinical Trial
A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Generalized Pustular Psoriasis
Summary
The main objectives of this study are to evaluate the efficacy, safety and tolerability of imsidolimab in adults with active GPP.
Eligibility Criteria
Inclusion Criteria:
Diagnosis of active GPP
Japanese Dermatology Association (JDA) severity index total score of at least 6 and erythema with pustules accounting for at least 10% of body surface area or a moderate severity score on Generalized Pustular Psoriasis Physician's Global Assessment (GPPPGA)
Must be candidates for systemic therapy or phototherapy
Exclusion Criteria:
Erythrodermic, guttate psoriasis, drug induced GPP
Any other ongoing inflammatory disease that interfere with the Investigator's ability to evaluate the subject's response to therapy
History of recurrent or chronic infection
ongoing use of psoriasis prohibited medication
Other protocol-defined inclusion/exclusion criteria may apply
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 9 Locations for this study
Encino California, 91436, United States
Largo Florida, 33771, United States
Miami Florida, 33316, United States
Indianapolis Indiana, 46250, United States
Ann Arbor Michigan, 48109, United States
Seoul , 03722, Korea, Republic of
Olsztyn , 10-22, Poland
Rzeszów , 35-05, Poland
Åódź , 90-43, Poland
Åódź , , Poland
London , , United Kingdom
Newcastle Upon Tyne , , United Kingdom
Salford , , United Kingdom
How clear is this clinincal trial information?
